文献报告指出:在肾小球肾炎,肾病综合征均存在着纤溶低下的病理改变,应用纤溶活性药物——尿漱酶(urokinase),则有减少或避免纤维蛋白沉着的作用。本文总结31个医疗单位协作观察的92例患者,其中慢性肾炎36例、肾病综合征50例(原发性39例,继发性11例)、急性肾炎3例、亚急性肾炎3例经应用尿激酶60,000U/d(溶于生理盐水或5％葡萄糖液250ml中,每日1次,静脉滴注),连续使用14天。对其临床症状改善率、全改善率、全有用率给以评价,同时对照了治疗前和病程后的临床实验室资料(尿量、尿蛋白量、肌酐清除率等)。结果①临床症状改善率:慢性肾炎71.4％,原发性肾病综合征56.3％,继发性肾病综合征44.4％。在全部34例中,有58.8％。②全改善率:原发性肾病综合征46.2％,继发性肾病综合征45.5％,在全部92例中,为45.7％。③全有用率:原发性肾病综合征 Reported in the literature: In glomerulonephritis, nephrotic syndrome fibrinolytic low pathological changes exist, the application of fibrinolytic active drugs - urine enzyme (urokinase), there is to reduce or avoid the role of fibrinosis. This article summarizes the 92 patients in 31 medical units collaboratively observed, of which 36 cases of chronic nephritis, nephrotic syndrome in 50 cases (39 cases of primary, 11 cases of secondary), acute nephritis in 3 cases, 3 cases of subacute nephritis by application Urokinase 60,000U / d (dissolved in 250ml normal saline or 5% glucose solution, once daily, intravenous infusion) for 14 consecutive days. Clinical symptom improvement rate, total improvement rate and full utilization rate were evaluated, and clinical laboratory data (urine output, urinary protein, creatinine clearance, etc.) before and after treatment were compared. Results ① The improvement rate of clinical symptoms: chronic nephritis 71.4%, primary nephrotic syndrome 56.3%, secondary nephrotic syndrome 44.4%. In all 34 cases, 58.8%. ② The overall improvement rate: primary nephrotic syndrome 46.2%, secondary nephrotic syndrome 45.5%, in all 92 cases, 45.7%. ③ all-purpose rate: primary nephrotic syndrome